Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG

LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE

Standard Dose
150MG; 300MG; 200MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG is listed in Drugs@FDA under application 022356 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 150MG; 300MG; 200MG Sponsor HETERO DRUGS LTD Submission history Latest submission status date: 2009-05-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG is listed in Drugs@FDA under application 022356 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE Form and strength TABLET; ORAL - 150MG; 300MG; 200MG Sponsor HETERO DRUGS LTD Submission history Latest submission status date: 2009-05-07 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
LAMIVUDINE, ZIDOVUDINE TABS 150MG/300MG CO-PACKAGED WITH NEVIRAPINE TABS 200MG (LAMIVUDINE; ZIDOVUDINE; NEVIRAPINE) | Drug Monograph | MedicHelpline